Result of AGM
26 April 2019 17:45 BST
Results of Annual General Meeting held on 26 April 2019
AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 – 8 were passed as ordinary resolutions and resolutions 9 – 12 were passed as special resolutions.
| RESOLUTION | VOTES FOR | % OF VOTES CAST | VOTES AGAINST | % OF VOTES CAST | VOTES CAST IN TOTAL | TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL | VOTES WITHHELD | |
| 1 | To receive the Company’s Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2018 | 1,002,386,773 | 99.96 | 381,361 | 0.04 | 1,002,768,134 | 76.44% | 2,130,013 |
| 2 | To confirm dividends | 1,000,878,921 | 99.65 | 3,545,943 | 0.35 | 1,004,424,864 | 76.57% | 474,696 |
| 3 | To reappoint PricewaterhouseCoopers LLP as Auditor | 1,003,208,151 | 99.90 | 1,002,311 | 0.10 | 1,004,210,462 | 76.55% | 688,850 |
| 4 | To authorise the Directors to agree the remuneration of the Auditor | 1,002,479,345 | 99.82 | 1,794,309 | 0.18 | 1,004,273,654 | 76.56% | 625,255 |
| 5a | To re-elect Leif Johansson as a Director | 998,953,618 | 99.51 | 4,884,897 | 0.49 | 1,003,838,515 | 76.53% | 1,060,758 |
| 5b | To re-elect Pascal Soriot as a Director | 1,001,460,120 | 99.73 | 2,740,412 | 0.27 | 1,004,200,532 | 76.55% | 699,226 |
| 5c | To re-elect Marc Dunoyer as a Director | 997,205,236 | 99.31 | 6,915,112 | 0.69 | 1,004,120,348 | 76.55% | 775,679 |
| 5d | To re-elect Geneviève Berger as a Director | 993,018,194 | 99.77 | 2,314,964 | 0.23 | 995,333,158 | 75.88% | 9,563,029 |
| 5e | To re-elect Philip Broadley as a Director | 995,659,475 | 99.16 | 8,475,542 | 0.84 | 1,004,135,017 | 76.55% | 761,114 |
| 5f | To re-elect Graham Chipchase as a Director | 958,824,389 | 97.22 | 27,400,052 | 2.78 | 986,224,441 | 75.18% | 18,671,390 |
| 5g | To re-elect Deborah DiSanzo as a Director | 1,001,808,208 | 99.77 | 2,336,040 | 0.23 | 1,004,144,248 | 76.55% | 751,639 |
| 5h | To re-elect Sheri McCoy as a Director | 1,000,164,666 | 99.60 | 3,984,489 | 0.40 | 1,004,149,155 | 76.55% | 746,732 |
| 5i | To elect Tony Mok as a Director | 1,003,431,827 | 99.93 | 699,122 | 0.07 | 1,004,130,949 | 76.55% | 764,625 |
| 5j | To re-elect Nazneen Rahman as a Director | 1,001,687,441 | 99.76 | 2,413,171 | 0.24 | 1,004,100,612 | 76.55% | 795,505 |
| 5k | To re-elect Marcus Wallenberg as a Director | 908,178,624 | 90.44 | 96,025,641 | 9.56 | 1,004,204,265 | 76.55% | 691,663 |
| 6 | To approve the Annual Report on Remuneration for the year ended 31 December 2018 | 947,606,599 | 95.86 | 40,895,170 | 4.14 | 988,501,769 | 75.36% | 16,392,056 |
| 7 | To authorise limited political donations | 977,701,447 | 97.87 | 21,290,398 | 2.13 | 998,991,845 | 76.16% | 5,895,452 |
| 8 | To authorise the Directors to allot shares | 877,861,679 | 87.43 | 126,178,566 | 12.57 | 1,004,040,245 | 76.54% | 853,485 |
| 9 | To authorise the Directors to disapply pre-emption rights | 990,106,053 | 98.92 | 10,841,253 | 1.08 | 1,000,947,306 | 76.31% | 3,944,848 |
| 10 | To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments | 979,272,055 | 97.83 | 21,681,201 | 2.17 | 1,000,953,256 | 76.31% | 3,939,912 |
| 11 | To authorise the Company to purchase its own shares | 994,069,976 | 99.04 | 9,657,377 | 0.96 | 1,003,727,353 | 76.52% | 1,164,722 |
| 12 | To reduce the notice period for general meetings | 905,789,402 | 90.67 | 93,205,859 | 9.33 | 998,995,261 | 76.16% | 5,902,125 |
Issued capital
As at 24 April 2019, the number of issued shares of the Company was 1,311,759,192 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company’s Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in its main therapy areas - Oncology, CVRM and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.
| Media Relations | ||
| Gonzalo Viña | UK/Global | +44 203 749 5916 |
| Rob Skelding | UK/Global | +44 203 749 5821 |
| Matt Kent | UK/Global | +44 203 749 5906 |
| Jennifer Hursit | UK/Global | +44 203 749 5762 |
| Christina M Hägerstrand | Sweden | +46 8 552 53 106 |
| Michele Meixell | US | +1 302 885 2677 |
| Investor Relations | ||
| Thomas Kudsk Larsen | +44 203 749 5712 | |
| Henry Wheeler | Oncology | +44 203 749 5797 |
| Christer Gruvris | BioPharma - Cardiovascular; Metabolism | +44 203 749 5711 |
| Nick Stone | BioPharma - Respiratory; Renal | +44 203 749 5716 |
| Josie Afolabi | Other | +44 203 749 5631 |
| Craig Marks | Finance; Fixed Income | +44 7881 615 764 |
| Jennifer Kretzmann | Retail Investors; Corporate Access | +44 203 749 5824 |
| US toll-free | +1 866 381 72 77 | |
Adrian Kemp
Company Secretary
AstraZeneca PLC